Evaluation of scalene lymph node or contralateral mediastinum biopsy during mediastinoscopy for non-small cell lung cancer.
- Author:
Hui YU
1
;
Shi-yi ZHANG
;
Xin WANG
;
Ze-ming XIE
;
Jun-ye WANG
;
Yong LI
;
Xuan XIE
;
Jia-liang ZHOU
;
Lan-jun ZHANG
;
Jian-hua FU
Author Information
- Publication Type:Journal Article
- MeSH: Adenocarcinoma; blood; pathology; Adult; Aged; Biopsy; Carcinoembryonic Antigen; blood; Carcinoma, Non-Small-Cell Lung; blood; pathology; Female; Follow-Up Studies; Humans; Lung Neoplasms; blood; pathology; Lymph Nodes; pathology; Lymphatic Metastasis; Male; Mediastinoscopy; Mediastinum; Middle Aged; Neck Muscles; Neoplasm Staging
- From: Chinese Journal of Oncology 2009;31(10):780-782
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo explore the clinical indication of N3 lymph node biopsy during mediastinoscopy for non-small cell lung cancer (NSCLC).
METHODSCervical mediastinoscopy was performed in 89 patients with clinical stage I-IIIA non-small cell lung cancer prior to thoracotomy. Of those, 12 underwent cervical medistinoscopy combined with right scalene lymph node biopsy and 10 with anterior mediastinotomy.
RESULTSNine patients were found to have lymph node metastasis (N3 disease) during mediastinosopy. Of those, 6 had contralateral mediastinal lymph node metastasis and 3 cases with right scalene lymph node metastasis. The incidence of N3 disease in the patients with adenocarcinoma, serum CEA > 5 ng/ml and multi-station mediastinal lymph node metastasis was significantly higher than that in those with non-adenocarcinoma, CEA < 5 ng/ml and ipsilateral uni-station mediastinal lymph nodes metastasis (P < 0.05).
CONCLUSIONBiopsy of scalene lymph node or contralateral mediastinal lymph node should be performed during mediastinoscopy in order to exclude N3 disease for potentially operable NSCLC patients with adenocarcinoma, serum CEA >5 ng/ml and ipsilateral multi-station mediastinal lymph nodes metastasis.
